key: cord-0839984-e7dw0luk
authors: GULERSEN, Moti; ROCHELSON, Burton; SHAN, Weiwei; WETCHER, Cara S.; NIMAROFF, Michael; BLITZ, Matthew J.
title: Severe maternal morbidity in pregnant patients with severe acute respiratory syndrome coronavirus 2 infection
date: 2022-04-06
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2022.100636
sha: 456c8025f3451d8736e16ea64c0eb4d1ddbe8e57
doc_id: 839984
cord_uid: e7dw0luk

Background While the increased risk of severe illness and adverse pregnancy outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy are well described, the association of infection with severe maternal morbidity (SMM) has not been well characterized. Objective To evaluate the risk of SMM associated with SARS-CoV-2 infection in pregnancy. Study Design A multicenter retrospective cohort study of all pregnant patients who had SARS-CoV-2 testing and delivered in a New York health system between March 1st, 2020 and March 1st, 2021. Patients with missing test results were excluded. The primary outcome of SMM, derived from the American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine example list of diagnoses and complications, was compared between two groups: patients who tested positive for SARS-CoV-2 during pregnancy versus patients who tested negative. Secondary outcomes included subgroups of SMM. Multivariable logistic regression was used to adjust for potential confounders such as maternal demographics, neighborhood socioeconomic status, hospital location, and pregnancy-related complications. A subanalysis was performed to determine whether the risk of severe obstetrical hemorrhage and hypertension/neurologic morbidity differed based on timing of SARS-CoV-2 infection: those who tested positive for SARS-CoV-2 at their delivery hospitalization (i.e. active infection), and those who tested positive during pregnancy but negative at their delivery hospitalization (i.e. resolved infection). Results Of the 22,483 patients included, 1,653 (7.4%) tested positive for SARS-CoV-2 infection. Patients with SARS-CoV2 infection were more commonly Black, multiracial, Hispanic, non-English speaking, using Medicaid insurance, multiparous, and from neighborhoods with a lower socioeconomic status. Patients with SARS-CoV-2 infection were at an increased risk of SMM compared to those without infection (9.3 vs. 6.5%; adjusted OR 1.52, 95% CI 1.21-1.88). Patients with SARS-CoV-2 infection were also at an increased risk of severe obstetrical hemorrhage (1.1% vs. 0.5%; aOR 1.78, 95% CI 1.04-2.88), pulmonary morbidity (2.0% vs. 0.5%; aOR 3.90, 95% CI 2.52-5.89), and intensive care unit (ICU) admission (1.8% vs. 0.5%; aOR 3.29, 95% CI 2.09-5.04) compared to those without infection. The risk of hypertension/neurologic morbidity was similar between the two groups. Timing of SARS-CoV-2 infection (whether active or resolved at time of delivery) was not associated with the risk of severe obstetrical hemorrhage or hypertension/neurologic morbidity compared to those without infection. Conclusions SARS-CoV-2 infection in pregnancy is associated with an increased risk of SMM, severe obstetrical hemorrhage, pulmonary morbidity, and ICU admission. These data highlight the need for obstetrical unit preparedness in caring for patients with SARS-CoV-2 infection, continued public health efforts aimed at minimizing risk of infection and support including this select population in investigational therapy and vaccine trials.

Hispanic, non-English speaking, using Medicaid insurance, multiparous, and from neighborhoods with a lower socioeconomic status. Patients with SARS-CoV-2 infection were at an increased risk of SMM compared to those without infection (9.3 vs. 6.5%; adjusted OR 1.52, 95% CI 1.21-1.88). Patients with SARS-CoV-2 infection were also at an increased risk of severe obstetrical hemorrhage (1.1% vs. 0.5%; aOR 1.78, 95% CI 1.04-2.88), pulmonary morbidity (2.0% vs. 0.5%; aOR 3.90, 95% CI 2.52-5.89), and intensive care unit (ICU) admission (1.8% vs. 0.5%; aOR 3.29, 95% CI 2.09-5.04) compared to those without infection. The risk of hypertension/neurologic morbidity was similar between the two groups. Timing of SARS-CoV-2 infection (whether active or resolved at time of delivery) was not associated with the risk of severe obstetrical hemorrhage or hypertension/neurologic morbidity compared to those without infection.

Conclusions: SARS-CoV-2 infection in pregnancy is associated with an increased risk of SMM, severe obstetrical hemorrhage, pulmonary morbidity, and ICU admission. These data highlight the need for obstetrical unit preparedness in caring for patients with SARS-CoV-2 infection, continued public health efforts aimed at minimizing risk of infection and support including this select population in investigational therapy and vaccine trials.

Accumulating data have demonstrated that pregnant patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are at increased risk for severe illness and death due to complications from coronavirus disease 2019 (COVID-19) compared with patients who are not pregnant. 1,2 Furthermore, SARS-CoV-2 infection in pregnancy and higher levels of disease severity have been associated with a number of perinatal complications including hypertensive disorders of pregnancy, preterm birth, stillbirth, and cesarean delivery. [3] [4] [5] [6] [7] [8] [9] [10] As a result, public health efforts have highlighted the need for minimizing the risk of infection and supporting the inclusion of pregnant patients in investigational therapy and vaccine trials. 12, 12 Identifying health-impacting and life-threatening unintended outcomes that occur during labor and delivery has become an important initiative for healthcare organizations worldwide. [13] [14] [15] [16] [17] Quality committees often review these rare events, most commonly referred to as severe maternal morbidity, in order to address whether the outcome could have been avoided or changes in systems for care provision are needed. [15] [16] [17] Ultimately, employing strategies aimed at preventing or reducing the recurrence of these outcomes that may lead to maternal mortality help ensures quality obstetric care. 15 Due to the increasing rates of severe maternal morbidity in the United States, several professional groups including the American College of Obstetricians and Gynecologists (ACOG), Society for Maternal-Fetal Medicine (SMFM), and Centers for Disease Control and Prevention (CDC) have advocated for research aimed at identifying risk factors for severe maternal morbidity. 15 While the increased risk of severe illness and adverse pregnancy outcomes associated with SARS-CoV-2 infection in pregnancy are well described, 1-10 the association of infection with severe maternal morbidity has not been well characterized for events other than intensive care unit (ICU) admissions and ventilator use. Therefore, the objective of this study was to evaluate the association of severe maternal morbidity with SARS-CoV-2 infection in pregnancy.

This was a retrospective cohort study of all pregnant patients who had SARS-CoV-2 testing and delivered at seven hospitals within a large health system in New York between March 1 st , 2020 and March 1 st , 2021. Patients with missing test results were excluded. The Northwell Health Institutional Review Board approved this study as minimal-risk research using data collected for routine clinical practice and waived the requirement for informed consent. A subset of these patients has been included in previous publications evaluating outcomes associated with SARS-CoV-2 infection in pregnancy within our health system. [18] [19] [20] [21] [22] Two groups of patients were compared based on the results of their SARS-CoV-2 qualitative real-time polymerase chain reaction (PCR) test: those who tested positive for SARS-CoV-2 infection during pregnancy versus those who tested negative. Diagnosis of infection was confirmed via qualitative real-time PCR on maternal nasopharyngeal swab specimens. Universal testing for SARS-CoV-2 infection was implemented for all patients admitted to Labor and Delivery and antepartum units in all participating sites on April 2 nd , 2020. 22 Prior to April 2 nd , due to limited capabilities, testing was performed based on a clinical suspicion for SARS-CoV-2 infection (i.e. fever, flu-like symptoms, travel history, known or suspected exposure).

The primary outcome was a composite of severe maternal morbidity indicators listed in Table 1 , derived from the ACOG and SMFM example list of diagnoses and complications. 15 Their obstetric care consensus document, created in collaboration with multidisciplinary expert groups, is intended to outline the process of efficiently identifying cases of severe maternal morbidity and optimizing strategies to improve patient care through quality review. 15 Secondary outcomes included each classified subgroup of severe maternal morbidity: severe obstetrical hemorrhage (patients who had at least 1 of the following: obstetric hemorrhage requiring transfusion of 4 or more packed red blood cells, uterine artery embolization, or peripartum hysterectomy), hypertension/neurologic morbidity (patients who had at least 1 of the following: eclampsia, stroke, severe hypertension [≥160 mmHg systolic blood pressure or ≥110 mmHg diastolic blood pressure] requiring intravenous antihypertensive therapy, or hemolysis, elevated liver enzymes, and low platelet count [HELLP] syndrome), sepsis, pulmonary morbidity (patients who had at least 1 of the following: acute respiratory distress syndrome, pulmonary edema, mechanical ventilation, or deep vein thrombosis or pulmonary embolism) cardiac morbidity (patients who had at least 1 of the following: myocardial infarction or peripartum cardiomyopathy), and ICU admission. 15 Patient demographic information, clinical characteristics such as comorbid conditions (e.g. cardiovascular disease [defined as patients with a history of cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, valvular disease, heart failure, and thromboembolic disease]), pregnancy outcomes, and the presence of any of the defined severe maternal morbidity indicators were obtained from our institution's electronic health record system (Sunrise Clinical Manager; Allscripts) ( Table 2 ). Severe maternal morbidity events were identified from physician clinical documentation and International Classification of Diseases (ICD), 10 th revision, diagnosis and procedural codes. Race and ethnicity were self-reported from prespecified categories. Patient zone improvement plan (ZIP) codes were linked to neighborhood-level data (i.e. annual household income, household size, proportions of occupants who are receiving supplemental income, have low education levels and are in owner occupied or single parent housing) from the United States Census Bureau's American Community Survey. 24 Statistical analysis included use of chi-squared test or Fisher's exact test and Mann-Whitney U test or Student's t test for comparisons of categorical and continuous variables, as appropriate.

Backwards-stepwise multivariable logistic regression was performed to evaluate the association between SARS-CoV-2 infection and severe maternal morbidity, while adjusting for the following potential confounders: maternal age, BMI, race, ethnicity, parity, insurance type, neighborhood-level characteristics, hospital location, comorbid conditions (i.e. chronic hypertension, asthma, cardiovascular disease), gestational diabetes, hypertensive disorders of pregnancy (gestational hypertension or preeclampsia), mode of delivery and gestational age at delivery (see Table 2 for categorization of each variable). The potential confounders included all baseline characteristics that were significantly different between the two groups and others such as hospital location, as both tertiary care and community-based hospitals were included in our study. We then used backwards-stepwise logistic regression to select a model in which the least significant factors were removed. The best model was selected based on the fitness determined by Akaike information criterion and log likelihood.

A subanalysis was performed to determine whether the risk of severe obstetrical hemorrhage and hypertension/neurologic morbidity differed based on timing of SARS-CoV-2 infection. For this analysis, patients with a positive SARS-CoV-2 PCR test were further divided into two groups: those who tested positive for SARS-CoV-2 at their delivery hospitalization (i.e. active infection), and those who tested positive during pregnancy but negative at their delivery hospitalization (i.e. resolved infection). Patients who only had negative testing during their pregnancy and delivery hospitalization represented the reference group. Only these two morbidity subgroups were selected because they are most often peripartum complications, whereas others such as ICU admission, ARDS, and ventilator use may have occurred earlier in pregnancy. Data were presented as adjusted odds ratios (aOR) with 95% confidence intervals (95% CI) and statistical significance set at P < 0.05.

During the study period, a total of 28,334 pregnant patients were admitted for delivery. Patients with missing SARS-CoV-2 test results (n = 5,896) were excluded. Of the remaining 22,483 patients included in our cohort, 1,653 (7.4%) tested positive for SARS-CoV-2 infection during their pregnancy and 20,785 (92.6%) tested negative. Baseline characteristics compared between the two groups are presented in Table 2 . Patients with SARS-CoV-2 infection were more commonly Black, multiracial, Hispanic, non-English speaking, using Medicaid insurance, multiparous, and from neighborhoods with a lower socioeconomic status ( Table 2 ). There were also high rates of medical comorbidities such as pregestational diabetes and cardiac disease in the SARS-CoV-2 positive group ( Table 2) . Pregnancy-related complications such as gestational hypertension, preeclampsia, and gestational diabetes, as well as mode of delivery were similar between the two groups ( Table 2 ).

The risk of composite severe maternal morbidity was significantly increased in patients with SARS-CoV-2 infection compared to those without infection (9.3% vs. 6.5%; aOR 1.52, 95% CI 1.21-1.88) ( Table 3) . Patients with SARS-CoV-2 infection were also at an increased risk of severe obstetrical hemorrhage (1.1% vs. 0.5%; aOR 1.78, 95% CI 1.04-2.88), pulmonary morbidity (2.0% vs. 0.5%; aOR 3.90, 95% CI 2.52-5.89), and ICU admission (1.8% vs. 0.5%; aOR 3.29, 95% CI 2.09-5.04) compared to those without infection ( Table 3 ). The risk of hypertension/neurologic morbidity was similar between the two groups ( Table 3 ). The incidences of cardiac morbidity (n = 16) and sepsis (n = 54) in our cohort were low, and thus not evaluated in our regression analysis.

Baseline characteristics compared between patients with and without composite severe maternal morbidity in each SARS-CoV-2 group (positive or negative) are presented in Table 4 . Among patients with SARS-CoV-2 infection, those who had severe maternal morbidity were older, had a higher BMI, were more commonly Black or Asian, had higher rates of medical comorbidities such as cardiovascular disease, asthma, chronic hypertension, and pregestational diabetes, and delivered at an earlier median gestational age, compared to those without severe maternal morbidity (Table 4 ). Similar differences in baseline characteristics were also seen among patients without SARS-CoV-2 infection who had severe maternal morbidity compared to those without severe maternal morbidity (Table 4) .

A comparison of the rates of primary and secondary outcomes between the first and second half of the study period is displayed in Table 5 . There was a significant increase in composite severe maternal morbidity during the second half of the study period compared to the first half (7.4% vs. 6.7%, P = 0.03) ( Table 5 ). The rates of severe maternal morbidity subgroups were similar between the two groups (Table 5 ). There was also a similar significant increase in composite (Table 6 ).

The results of this study illustrate that SARS-CoV-2 infection in pregnancy is associated with an increased risk for composite severe maternal morbidity and several subgroups of severe maternal morbidity such as severe obstetrical hemorrhage, pulmonary morbidity, and ICU admission.

Timing of SARS-CoV-2 infection, whether active or resolved at the time of delivery, was not associated with the risk of severe obstetrical hemorrhage or hypertension/neurologic morbidity.

Evaluations of the association between severe maternal morbidity and SARS-CoV-2 infection in pregnancy have been heterogeneous with respect to classification of outcomes. 1, 25, 26 Our findings of an increased risk of pulmonary morbidity and ICU admission associated with SARS-CoV-2 infection in pregnancy are similar to previous reports from the CDC and other international cohort studies. 1, 25, 26 However, an assessment of the risk of severe maternal morbidity, defined based on indicators reported in national or international guidelines, has rarely been explored to date. In a prospective observational cohort of 2,130 patients from 18 countries, the INTERCOVID investigators reported an increased risk of composite maternal morbidity and mortality index associated with COVID-19 in pregnancy (31.9% vs. 20.8%; relative risk 1.54, 95% CI 1.33-1.78). 25 Although the 12 maternal deaths (0.6% of total cohort) were included in their composite outcome, the much higher incidence of morbidity in their study compared to ours is likely secondary to their defined maternal morbidity index, which included relatively common complications such as third-trimester bleeding, pregnancy-induced hypertension, infections requiring antibiotics, and preterm labor. 25 4 In their primary adjusted analysis, higher COVID-19 severity was associated with a higher risk of postpartum hemorrhage. 4 These findings are in contrast to a smaller retrospective cohort study by Wang and colleagues, who reported no association between obstetric hemorrhage (defined as blood loss greater than 1,000 mL measured quantitatively at the time of delivery) and COVID-19 in pregnancy. 27 Differences in study design, definition of hemorrhage, and sample size likely contribute to the conflicting results reported in the literature.

Our findings of SARS-CoV-2 infection representing a risk factor for severe maternal morbidity, defined from ACOG and SMFM's obstetric care consensus document, highlight the importance of encouraging practices to reduce such risk. In addition, our findings of an increased risk of severe obstetrical hemorrhage associated with SARS-CoV-2 infection inform hospitals and clinicians caring for pregnant patients with SARS-CoV-2 infection to have blood products and medical interventions such as uterotonics available at the time of delivery. Furthermore, given this significant risk in addition to other severe morbidities associated with SARS-CoV-2 infection in pregnancy, patient transfer to higher-level care and alerting appropriate surgical or interventional radiological consultants should be considered.

The novel coronavirus' characteristic as primarily a respiratory pathogen coupled with an increased susceptibility to hypoxemia due to pregnancy-associated anatomical and physiological changes likely contributes to the increased risk of pulmonary morbidity and ICU admission associated with SARS-CoV-2 infection. 28 The underlying etiology for severe obstetrical hemorrhage is less clear. Possible mechanisms include pathological vascular changes such as endothelial dysfunction that are induced by the virus. 29, 30 Furthermore, coagulopathy has been described in pregnant patients with severe illness. 31 It is possible that placental evaluation may provide additional insight regarding the pathophysiology of this association. However, placental evaluation of these cases was not available for analysis, as placentas are not routinely sent to our Pathology department for examination at our institution. Nevertheless, the contribution of these hypotheses to hemorrhage, along with the potential impact of the accompanying release of large amounts of pro-inflammatory cytokines after infection, 32 requires further study.

Of note, we evaluated whether timing of SARS-CoV-2 infection was associated with the risk of severe obstetrical hemorrhage or hypertension/neurologic morbidity and found no such association. While these data suggest earlier infection and subsequent resolution do not confer a higher risk may be reassuring, the incidence of these outcomes were relatively low, which may have limited the power to detect significant differences. Future studies exploring the association of timing of infection with adverse perinatal outcomes and severe morbidities are needed.

This study has several strengths. We address an important topic of severe maternal morbidity, which carries a significant burden for healthcare organizations around the world and where efforts to develop interventions to reduce this risk are of importance. Additionally, our severe maternal morbidity indicators were obtained from a joint document supported by ACOG, SMFM, and the CDC. 15 Our multicenter cohort is derived from both tertiary care and community-based hospitals in New York, which is diversified in terms of maternal demographics and neighborhood socioeconomic status, thus making our findings generalizable.

Our health system performs nearly 30,000 deliveries annually (1% of the United States population of births), allowing our cohort to be among the largest reported in the literature evaluating outcomes associated SARS-CoV-2 infection in pregnancy.

This study also has several limitations. Our analysis was retrospective and relied on identifying severe maternal morbidity events from physician clinical documentation and ICD diagnosis codes. As a result, the timing of adjusted variables such as the diagnosis of preeclampsia or gestational hypertension may have occurred at the time as severe maternal morbidity or earlier in pregnancy. We were also unable to assess the association of COVID-19 disease severity with our primary and secondary outcomes. Universal testing for SARS-CoV-2 infection was not performed throughout the entire study period. However, given that it was implemented across our health system in all months but one, it is likely that this would not impact the findings of our study. Our study period also includes more than one wave of SARS-CoV-2 infection during the COVID-19 pandemic. Although variants of SARS-CoV-2 infection may have different risk profiles for disease severity and severe morbidity in pregnant patients, evaluation this association was not the focus of our study. Although adjusted for in our multivariable analysis, there were several significant differences at baseline between groups, which have been independently associated with an increased risk of SARS-CoV-2 infection and may have contributed to our findings. Furthermore, there may have been potential factors such as changes in patient population characteristics as a result of outmigration during the COVID-19 pandemic, which were not adjusted for and may have contributed to our findings. Lastly, our study period spans a year where treatments for COVID-19 and interventions to help reduce the risk of infection such as vaccination were rapidly evolving. We were unable to examine the impact of these practices on severe maternal morbidity.

In conclusion, our findings illustrate that SARS-CoV-2 infection in pregnancy is associated with an increased risk of composite severe maternal morbidity, severe obstetrical hemorrhage, pulmonary morbidity, and ICU admission. As we enter another wave of the pandemic with record-setting infection rates, these data highlight the need for continued public health efforts aimed at minimizing risk of infection and promoting vaccination and investigational therapies in this select patient population. Preliminary data evaluating the impact of vaccination on SARS-CoV-2 infection rates and COVID-19 disease severity in pregnancy have been reassuring. 33 Continuing to identify risk factors for severe maternal morbidity and implementation of hospital guidelines to help reduce the incidence of severe maternal morbidity remains an important step in promoting safe obstetric care and guide patient counseling. Data presented as median (interquartile range) and n (%). Missing data for 11.4% of body mass index, 8.9% of parity, 1.2% of insurance type, 3.1% of median annual household income, 1.1% of education less than high school, 1% of median household size, 1% of households receiving supplemental income, 1% of single parent household, 1% of owner occupied housing, 1% of unemployment, 0.3% of mode of delivery, 0.3% of gestational age at delivery, and <0.1% of language. Cardiac morbidity en (%) 8 (0.1) 8 (0.1) 0.8 ICU admissionn (%) 65 (0.6) 66 (0.6) 0.5 a Includes patients with at least 1 of the following complications during pregnancy: obstetric hemorrhage requiring transfusion of 4 or more packed red blood cells, uterine artery embolization, peripartum hysterectomy, eclampsia, stroke, severe hypertension requiring antihypertensive therapy, HELLP syndrome, sepsis, acute respiratory distress syndrome, pulmonary edema, mechanical ventilation, venous thromboembolism, myocardial infarction, peripartum cardiomyopathy, or ICU admission b Includes patients with at least 1 of the following: obstetric hemorrhage requiring transfusion of 4 or more packed red blood cells, uterine artery embolization, or peripartum hysterectomy c Includes patients with at least 1 of the following: eclampsia, stroke, severe hypertension requiring antihypertensive therapy, or HELLP syndrome d Includes patients with at least 1 of the following: acute respiratory distress syndrome, pulmonary edema, mechanical ventilation, or venous thromboembolism e Includes patients with at least 1 of the following: myocardial infarction, peripartum cardiomyopathy

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and metaanalysis

Disease Severity and Perinatal Outcomes of Pregnant Patients with Coronavirus Disease 2019 (COVID-19)

Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study

Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis

Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Systematic Review

Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study

Risk of Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization -United States

Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study

COVID-19 vaccines: interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States

American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19: practice advisory

WHO maternal death and near-miss classifications

Where is the "M" in maternal-fetal medicine?

American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine

Facility-based identification of women with severe maternal morbidity: it is time to start

Standardized severe maternal morbidity review: rational and process

Universal testing for coronavirus disease 2019 in pregnant women admitted for delivery: prevalence of peripartum infection and rate of asymptomatic carriers at four New York hospitals with an integrated healthcare system

Maternal mortality among women with coronavirus disease 2019 admitted to the intensive care unit

Clinical implications of SARS-CoV-2 infection in the viable preterm period

Social determinants of health and coronavirus disease 2019 in pregnancy

Preterm birth among women with and without severe acute respiratory syndrome coronavirus 2 infection

The care of pregnant women during the COVID-19 pandemic -response of a large health system in metropolitan New York

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

Obstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: A national retrospective cohort study

Obstetric Hemorrhage Risk Associated with Novel COVID-19 Diagnosis from a Single-Institution Cohort in the United States

Severe maternal morbidity and mortality associated with COVID-19: The risk should not be downplayed

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiongenesis in Covid-19

Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19

Coagulopathy in COVID-19

Why are pregnant women susceptible to COVID-19? An immunological viewpoint

Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared With Unvaccinated Pregnant Patients

Data presented as adjusted odds ratios with 95% confidence intervals. a Includes patients with at least 1 of the following: obstetric hemorrhage requiring transfusion of 4 or more packed red blood cells, uterine artery embolization, or peripartum hysterectomy b Includes patients with at least 1 of the following: eclampsia, stroke, severe hypertension requiring antihypertensive therapy, or HELLP syndrome * Models adjusted for maternal age, body mass index, race, ethnicity, parity, insurance type, neighborhood-level characteristics, hospital location, comorbid conditions, gestational diabetes, hypertensive disorders of pregnancy (gestational hypertension or preeclampsia), mode of delivery, and gestational age at delivery.